Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Açaí Berry COVID-19 Anti-Inflammation Trial (ACAI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04404218
Recruitment Status : Recruiting
First Posted : May 27, 2020
Last Update Posted : August 7, 2020
Sponsor:
Collaborator:
University of Toronto
Information provided by (Responsible Party):
Michael Farkouh, University Health Network, Toronto

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : May 2021
Publications:
Machado AK, Cadoná FC, Assmann CE, Andreazza AC, Duarte MMMF, Branco CS, Zhou X, Souza DV, Ribeiro EE, Cruz IBM. Açaí (Euterpe oleracea Mart.) has anti-inflammatory potential through NLRP3-inflammasome modulation. Journal of Functional Foods. Volume 56, 2019, Pages 364-371, https://doi.org/10.1016/j.jff.2019.03.034.